Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.
about
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerBreaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticlesMetformin as a new anti-cancer drug in adrenocortical carcinomaThe impact of type 2 diabetes and antidiabetic drugs on cancer cell growthEmerging therapy for adrenocortical carcinoma.Current and emerging therapies for advanced adrenocortical carcinoma.Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.The insulin and igf-I pathway in endocrine glands carcinogenesisCurrent and emerging therapeutic options in adrenocortical cancer treatment.General molecular biology and architecture of nuclear receptors.Insulin-like growth factor--phosphatidylinositol 3 kinase signaling in canine cortisol-secreting adrenocortical tumors.Interaction between Angiotensin II and Insulin/IGF-1 Exerted a Synergistic Stimulatory Effect on ERK1/2 Activation in Adrenocortical Carcinoma H295R CellsClassic Cushing's syndrome in a patient with adrenocortical carcinoma.Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma.A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.Adrenocortical tumors and insulin resistance: What is the first step?A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
P2860
Q21328702-2FA18109-00F0-4818-B787-6A09F53E4E4BQ26830366-A03191C3-019D-41B0-A3C2-A926A49B6798Q28468634-F8DC8F19-2388-445D-BA04-044DF1AC8E0EQ34095570-A0394D9A-A036-4A28-8CA4-8B9B37814900Q35018399-949F1C7F-0B70-4C42-86A6-9329D8415FAFQ35584305-574D7605-E9CF-4783-A163-21F032F013CAQ36059702-D7586A04-E489-40A5-9CEF-8541FE7941A9Q36178421-669AFF80-5F46-42D7-B8B8-83BB650A2DBEQ36183873-F954588D-8AF5-41A2-A9B8-F6F2A7068FCBQ36797684-1DAB0E26-4AE1-4E17-BCA1-49B400CAFCEFQ36873574-48164519-73AB-459A-A7A8-741CEBA20363Q36936792-AB8B1673-42FA-41D1-8E19-32C4039F7A88Q36987132-3A781F8C-0858-4590-8D09-EEF7710BA830Q37366222-DFEFEA8F-95A2-4DDC-81C2-509CC2194466Q37683288-4FF71E81-6691-49D3-B501-68488AD9DFE2Q38659703-780C2002-E84F-429D-B964-D1E4090BDF1FQ53286031-3A7DBF6C-D953-4FF9-92BC-3D387E492BD6
P2860
Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@en
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@nl
type
label
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@en
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@nl
prefLabel
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@en
Rosiglitazone inhibits adrenoc ...... GF-IR intracellular signaling.
@nl
P2093
P2860
P356
P1433
P1476
Rosiglitazone inhibits adrenoc ...... IGF-IR intracellular signaling
@en
P2093
Adriana Lombardi
Elisabetta Ceni
Elisabetta Piscitelli
Giada Poli
Giulia Cantini
Mario Serio
Massimo Mannelli
Sara Marchiani
Tonino Ercolino
P2860
P304
P356
10.1155/2008/904041
P577
2008-07-28T00:00:00Z